We know that many of you have questions about what last week’s approval of a third COVID-19 vaccine dose means for IBD patients. We have spoken with our medical experts who have explained that, based on the guidance from the U.S. Food and Drug Administration, Centers for Disease Control and Prevention, and the CDC Advisory Committee on Immunization Practices, patients with IBD on a high-dose corticosteroid, anti-TNF biologics or biosimilars, and immunomodulators may receive a third dose of the vaccine. Patients on other therapies should discuss the merits of an additional dose with their healthcare provider.
In this video chat, Drs. David Rubin (University of Chicago Medicine), Meena Bewtra (University of Pennsylvania), and Freddy Caldera (University of Wisconsin) discuss what IBD patients need to know about this new approval. You can learn more about our position on COVID-19 vaccines on our website: https://bddy.me/2W7DdJK
0 Comments